What Sleep Aid Can I Take With Sleep Apnea?

Several sleep aids have been studied in people with obstructive sleep apnea and found not to worsen breathing during sleep, but none of them are universally safe, and the best choice depends on your specific situation. Melatonin receptor agonists, certain newer prescription hypnotics called dual orexin receptor antagonists, and low-dose trazodone all have data suggesting they can help with sleep without making apnea worse. At the same time, some widely used medications, including gabapentin and traditional sedatives, can actually increase the number of breathing disruptions you experience each night. The research here has evolved considerably in the last decade, and the picture is more nuanced than “just avoid all sleeping pills.”

Melatonin and Ramelteon

Melatonin is the sleep aid most people with sleep apnea reach for first, and the logic is sound. It works by nudging your circadian rhythm rather than sedating the muscles of your airway, so it carries a low theoretical risk of making apnea worse. Over-the-counter melatonin has not been studied as rigorously in sleep apnea populations as some prescription options, but ramelteon, a prescription drug that activates the same melatonin receptors, has been tested directly. In a controlled trial of people with mild to moderate obstructive sleep apnea, ramelteon produced virtually no change in the number of breathing events per hour compared to placebo, and oxygen saturation stayed the same throughout the night.¹ For people whose apnea is mild and whose main problem is difficulty falling asleep, melatonin or ramelteon is about as low-risk as it gets. The downside is that these are modest sleep promoters. If your insomnia is severe, they may not do enough.

Dual Orexin Receptor Antagonists

A newer class of prescription sleep medications, known as dual orexin receptor antagonists, or DORAs, works by blocking the brain’s wakefulness signals rather than broadly sedating the central nervous system. Suvorexant (Belsomra) and lemborexant (Dayvigo) are the best-known drugs in this class. Because they target a specific wakefulness pathway instead of depressing muscle tone throughout the body, researchers have been interested in whether they are safer for people with sleep apnea than older sedatives.

A recent systematic review and meta-analysis of randomized controlled trials found that DORAs improved sleep without increasing the number of apnea events per hour and did not increase the percentage of sleep time spent at dangerously low oxygen levels.² The adverse-effect profile was also comparable to placebo. For people who need something stronger than melatonin but want to avoid the respiratory risks of older sedatives, DORAs are an increasingly attractive option. They do require a prescription, and they can cause next-morning grogginess in some people, but the respiratory safety data so far is reassuring.

Z-Drugs Like Zolpidem and Eszopiclone

Zolpidem (Ambien) and eszopiclone (Lunesta) are among the most commonly prescribed sleep medications in general, so it matters a lot whether they are safe with sleep apnea. The answer is more complicated than you might expect, and it depends partly on which of the two you are taking.

A meta-analysis that pooled six studies of zolpidem in sleep apnea patients found essentially no change in the number of breathing events per hour compared to placebo or no medication. Individual responses were variable, with some people worsening and others improving, but across the group the effect was statistically insignificant.³ A separate open-label pilot study confirmed this variability, reporting no overall systematic difference in apnea severity, event duration, or oxygen levels between zolpidem nights and baseline nights.⁴

Eszopiclone may actually have a slight edge. The same meta-analysis found that across four studies with over 360 patients, eszopiclone was associated with a modest reduction in apnea events per hour.³ A Cochrane systematic review also flagged one trial where a single dose of eszopiclone significantly decreased apnea events compared with placebo.⁵ However, a more recent systematic review and meta-analysis cautioned that neither drug should be used as a standalone treatment for sleep apnea, and that prescribing hypnotics for apnea should generally be discouraged except in patients who also have insomnia or those with a specific breathing trait called a very low arousal threshold.⁶

The practical takeaway: if your doctor has prescribed zolpidem or eszopiclone and you also have sleep apnea, the evidence suggests these drugs probably won’t make your breathing dramatically worse on average. But “won’t worsen apnea” is not the same as “will treat apnea,” and individual responses vary enough that you should not assume your experience will match the group average.

Trazodone

Trazodone is a sedating antidepressant that many doctors prescribe off-label for insomnia. It has an interesting profile in sleep apnea research. One small but well-designed study found that trazodone reduced the number of apnea events from about 39 per hour to roughly 29 per hour compared with placebo, without worsening oxygen levels or making individual breathing events last longer.⁷ In another study focused on people with a low arousal threshold, meaning they wake up too easily in response to mild airway obstruction, trazodone raised that threshold by about a third. However, in that particular group, it did not change the overall number of apnea events.⁸

Why the different results? Sleep apnea has multiple underlying causes in different people. In some people, the problem is that their brain wakes them up at the slightest airway resistance, fragmenting sleep without giving the body a chance to stabilize breathing. For those people, raising the arousal threshold with trazodone can help. In others, the airway itself collapses too easily, and making it harder to wake up doesn’t fix that. Trazodone’s benefit depends on which mechanism is driving your apnea, which is something a sleep specialist can help figure out.

What to Avoid

Some common sleep-promoting substances are genuinely risky for people with sleep apnea. These are worth knowing about even if you haven’t been considering them, because some are available over the counter or prescribed for other conditions.

Gabapentin: Widely prescribed for nerve pain and sometimes used off-label for sleep, gabapentin nearly doubled the number of apnea events per hour in a randomized, placebo-controlled study of older men. The oxygen desaturation index also roughly doubled, and researchers calculated that the number needed to harm was just four, meaning for every four people given gabapentin, one experienced meaningfully worsened sleep breathing.⁹ If you take gabapentin for another condition and also have sleep apnea, this is worth discussing with your prescriber.
Benzodiazepines: Older sedatives like diazepam (Valium), lorazepam (Ativan), and clonazepam (Klonopin) relax muscles broadly, including the muscles that keep your airway open. They also reduce the brain’s drive to breathe. Sleep medicine guidelines have long treated benzodiazepines as contraindicated in untreated or undertreated sleep apnea.
Opioids: Prescription painkillers suppress the brainstem’s respiratory center. The risk compounds if you already have narrowing in your airway. Even short-acting opioids can increase both obstructive and central apnea events.
Alcohol: A meta-analysis found that higher alcohol consumption was associated with a roughly 25% increase in sleep apnea risk.¹⁰ Alcohol relaxes airway muscles in much the same way benzodiazepines do, and drinking before bed can turn mild apnea into moderate apnea for a night. This is one of the most easily modifiable risk factors.

Using Sleep Aids Alongside CPAP

If you already use a CPAP machine, you might assume that adding a sleep aid is harmless because the machine keeps your airway open. That’s partly true. CPAP does protect against most of the airway-collapse risk that makes sedatives dangerous, and some doctors will prescribe a mild sleep aid to help patients tolerate CPAP in the early weeks. However, a randomized trial that gave zolpidem to new CPAP users found no improvement in how many nights they used the machine or how many hours per night they kept it on, compared to placebo or standard care alone.¹¹ So the theory that a sleeping pill helps you get used to CPAP hasn’t held up particularly well in controlled testing.

There is one scenario where adding a hypnotic to CPAP therapy makes more sense: when you have both sleep apnea and a separate insomnia disorder, sometimes called COMISA (co-morbid insomnia and sleep apnea). In that situation, treating the insomnia component can improve your overall sleep quality and may even help you use CPAP more consistently. But the first-line treatment for the insomnia side is usually not a pill at all.

Cognitive Behavioral Therapy for Insomnia

If your difficulty sleeping isn’t purely caused by apnea but also involves trouble falling asleep, racing thoughts, or poor sleep habits, cognitive behavioral therapy for insomnia (CBT-I) is the most strongly supported non-drug approach. Multiple randomized controlled trials have shown that CBT-I improves sleep in people who have both insomnia and sleep apnea, and combining CBT-I with CPAP produces better results than CPAP alone.¹² CBT-I also appears to improve how consistently people use their CPAP, which is often the bigger battle.¹³

Access has historically been a barrier, since CBT-I requires a trained therapist and multiple sessions. Digital CBT-I programs delivered through apps or online platforms are emerging as an alternative, with early evidence suggesting they can be effective and safe for people with COMISA.¹⁴ If you find yourself reaching for a sleep aid mostly because you can’t shut your mind off at night, CBT-I addresses the root problem in a way that pills do not.

Weight-Loss Medications and Apnea Severity

This is a different category from traditional sleep aids, but it deserves attention because the data is striking. For people whose sleep apnea is driven substantially by excess weight, GLP-1 receptor agonists (the same class of drugs as semaglutide and tirzepatide, used for diabetes and weight management) can dramatically reduce apnea severity by reducing body weight itself.

In the SURMOUNT-OSA trial, participants with moderate-to-severe obstructive sleep apnea and obesity who received tirzepatide for a year saw their apnea events drop by roughly 25 to 30 events per hour on average, compared to a drop of about 5 to 6 events per hour in the placebo groups.¹⁵ That level of reduction moved many participants from severe apnea into mild or even normal range. A separate conference presentation of the same trial data reported that tirzepatide reduced apnea severity by roughly 55 to 63 percent, alongside an 18 to 20 percent reduction in body weight.¹⁶ A broader meta-analysis of GLP-1 receptor agonists in sleep apnea patients found an average reduction of about 14 events per hour, along with roughly 12 kilograms of weight loss.¹⁷

These drugs do not help you fall asleep on any given night. But if obesity is a major contributor to your apnea, they can reduce the severity of the underlying condition more effectively than any sleep aid. For some people, they may eventually reduce dependence on CPAP.

Acetazolamide for Central Sleep Apnea

Not all sleep apnea involves a physical airway collapse. Central sleep apnea, where the brain intermittently fails to send the signal to breathe, requires a different approach. Acetazolamide, a drug originally developed for altitude sickness and glaucoma, stimulates the respiratory drive by slightly shifting blood chemistry. In a meta-analysis focused specifically on central sleep apnea, acetazolamide significantly reduced apnea events.¹⁸ However, the same analysis found no statistically significant benefit for obstructive sleep apnea specifically.

A separate, larger meta-analysis reported a somewhat more favorable overall picture, with acetazolamide reducing apnea events by roughly 38 percent across both types and also improving the lowest overnight oxygen level by about 4 percentage points.¹⁹ The discrepancy between these analyses likely reflects differences in the studies included and how the analyses were structured, but the clearest evidence of benefit is in central apnea. Common side effects, including tingling in the fingers, altered taste, and fatigue, are dose-dependent, and the drug is generally used short-term or in specific clinical situations rather than as a nightly sleep aid.²⁰

Medications for Daytime Sleepiness From Sleep Apnea

Some people with sleep apnea continue to feel excessively sleepy during the day even after their apnea is being treated with CPAP or another device. This residual daytime sleepiness is a recognized problem, and there is now a medication specifically approved for it. Solriamfetol (brand name Sunosi) is a selective dopamine and norepinephrine reuptake inhibitor approved in the United States and the EU for excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy.²¹

Solriamfetol does not treat the apnea itself or help you fall asleep at night. It is a wakefulness-promoting agent, so it works during the daytime. In phase III trials, it improved wakefulness and reduced sleepiness scores at doses of 75 mg and 150 mg daily.²² If your main complaint is not that you can’t sleep at night but that you can’t stay awake during the day despite using CPAP, this is the category of medication to discuss with your doctor.

Experimental Approaches Worth Knowing About

Researchers are also testing drugs that target the apnea itself rather than simply promoting sleep around it. One line of research involves dronabinol, a synthetic version of THC. In a randomized trial, dronabinol reduced apnea events in a dose-dependent manner, with reductions of roughly 11 to 13 events per hour compared to placebo.²³ A follow-up study combined atomoxetine (a norepinephrine reuptake inhibitor) with dronabinol and found improvement at one dose combination, though a third of participants dropped out due to side effects.²⁴ These are not ready for routine clinical use, and the side-effect profiles need work. But they illustrate a broader shift in the field toward developing pharmacological treatments that address the mechanisms of apnea directly, rather than relying entirely on devices like CPAP.

The distinction between a drug that helps you sleep despite having apnea and a drug that treats the apnea itself is an important one. Most of the medications covered in this article fall into the first category. The emerging pharmacotherapies, along with GLP-1 receptor agonists for weight-related apnea, represent genuine attempts at the second. For now, though, if you have moderate-to-severe sleep apnea, none of these experimental agents are a substitute for proven treatments like CPAP, oral appliances, or weight loss.